News
Treatment Options for Dupuytren’s Contracture
The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture.Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Trends in DMARD Use in Juvenile Arthritis 2001-2022
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional DMARD use.
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
Predictors of Adverse Pregnancy Outcomes in Lupus
Anxiety and Depression Rising in Rheumatoid Arthritis
A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
